- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Inhibrx, Eikon rise after insider buying | 1 | Seeking Alpha | ||
| EIKON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.09. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer | 207 | GlobeNewswire (Europe) | MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 21.08. | Cantor Fitzgerald reiterates Overweight on Eikon stock | 1 | Investing.com | ||
| 18.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald | 2 | GlobeNewswire (USA) | ||
| 13.08. | Eikon Therapeutics, Inc. GAAP EPS of -$1.63 misses by $0.03 | 1 | Seeking Alpha | ||
| 13.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates | 224 | GlobeNewswire (Europe) | Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon's oncology portfolio, including clinical... ► Artikel lesen | |
| 13.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma | 449 | GlobeNewswire (Europe) | Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee... ► Artikel lesen | |
| 10.08. | Eikon Therapeutics adds Merck chemistry head to advisory board | 3 | Investing.com | ||
| 10.08. | Merck Chemiechef verstärkt wissenschaftlichen Beirat von Eikon Therapeutics | 4 | Investing.com Deutsch | ||
| 10.08. | Eikon Therapeutics, Inc.: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board | 419 | GlobeNewswire (Europe) | MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 03.08. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.07. | Eikon Therapeutics doses first patient in lung cancer trial | 1 | Investing.com | ||
| 27.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer | 190 | GlobeNewswire (Europe) | MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to... ► Artikel lesen | |
| 20.07. | Eikon Therapeutics, Inc.: Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress | 1 | GlobeNewswire (USA) | ||
| 25.06. | Eikon Therapeutics to join Russell 3000 index | 1 | Seeking Alpha | ||
| 25.06. | Eikon Therapeutics, Inc.: Eikon Therapeutics to Join the Russell 3000 Index | 158 | GlobeNewswire (Europe) | MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines... ► Artikel lesen | |
| 10.06. | Eikon Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Eikon Therapeutics beruft Ma. Fatima Francisco in den Verwaltungsrat | 2 | Investing.com Deutsch | ||
| 08.06. | Eikon Therapeutics appoints Francisco to board of directors | 1 | Investing.com |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,150 | +0,25 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,062 | -1,12 % | Inovio vor entscheidender FDA-Zulassung: Markteinführung von INO-3107 rückt näher | ||
| INFLARX | 1,847 | +2,73 % | InflaRx NV: Innovativer Ansatz gegen Entzündungskrankheiten im Fokus der Investoren | ||
| INTELLIA THERAPEUTICS | 10,160 | +0,40 % | Cathie Wood's ARK sells Twist Bioscience stock, buys more Intellia | ||
| EDITAS MEDICINE | 2,330 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,388 | -5,83 % | 7 Jahre in den USA, 10 Jahre in Europa: Was der Orphan-Status für NurExone wirklich wert ist | ||
| IBIO | 1,032 | 0,00 % | iBio auf Wells-Fargo-Gesundheitskonferenz: Pipeline gegen Adipositas nimmt Gestalt an | ||
| GERON | 1,201 | +3,27 % | Geron Corporation: Geron Announces Appointment of Chinmaya Rath as Chief Business Officer | FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| IMMUNITYBIO | 7,060 | +3,52 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,615 | +0,33 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 2,910 | -1,19 % | Myriad Genetics unter Druck: Fokus auf Krebstests soll Wende bringen | ||
| MANNKIND | 3,205 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 5,966 | +2,33 % | BTIG cuts Ginkgo Bioworks stock price target on transition concerns | ||
| IMMUNIC | 9,814 | -0,04 % | Stifel reiterates Immunic stock rating on MS drug potential | ||
| EMERGENT BIOSOLUTIONS | 5,080 | -5,40 % | Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes | Repurchase reduces unsecured note balance to approximately $364.7 millionManagement to discuss this key milestone and broader transformation progress at upcoming investor conferences GAITHERSBURG... ► Artikel lesen |
Das Unternehmen EIKON THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,11 % bei einem Aktienkurs von 8,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EIKON THERAPEUTICS INC finden Sie auf Wallstreet Online.